The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | Effective immunomodulation with pomalidomide during induction TST for AML and MDS
Joshua Zeidner, MD, of the UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, discusses the results of the Phase I dose escalation study (NCT02029950) assessing the safety and tolerability of pomalidomide administration after induction timed sequential therapy (TST) in newly diagnosed patients with acute myeloid leukemia (AML) or high-risk myelodysplasia (MDS). Speaking at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Dr Zeidner reveals that pomalidomide can be added at the time of early lymphocyte recovery (ELR) after induction TST without increased toxicity and with favourable response rates compared with previous controls.
